Inteliphage

Inteliphage is a Belgian biotechnology company specializing in the development of personalized bacteriophage therapies to address the global crisis of antimicrobial resistance (AMR). The company utilizes its proprietary PhageXpert™ platform, an AI-driven automated phagogram, to rapidly identify the most effective phages for a patient's specific bacterial infection within hours. Inteliphage maintains a diverse library of wild-type phages targeting the high-burden ESKAPE group of pathogens, which are responsible for the majority of life-threatening multi-drug resistant infections. By combining rapid diagnostics with scalable, GMP-ready manufacturing, the company provides an end-to-end solution for personalized infection treatment. Inteliphage is currently advancing its lead programs toward clinical application, with the goal of treating its first patients in 2026.